Sugi Predict

Sugi Predict / Compounds / Lithium

Lithium

Lithium

SCHEMBL7181101

COC(C)Oc1ccc(PC(=O)c2c(C(F)(F)F)cccc2C(F)(F)F)c(C)c1.[Li]

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.33
▸ PLA2G1B P04054 1/20 0.33
▸ ATG4B Q9Y4P1 1/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ AKR1C4 P17516 1/20 0.32
▸ AKR1C3 P42330 1/20 0.32
▸ AKR1C2 P52895 1/20 0.32
▸ AKR1C1 Q04828 1/20 0.32
▸ MAOB P27338 4/20 0.32
▸ MAOA P21397 1/20 0.32
▸ GAA P10253 2/20 0.31
▸ HPGD P15428 1/20 0.31
▸ LMNA P02545 2/20 0.31
▸ MAPT P10636 2/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ ATM Q13315 1/20 0.30
▸ NPSR1 Q6W5P4 1/20 0.30
▸ NR1H2 P55055 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7188242 0.89 PPARD (0.34) TDP1PLA2G1BATG4BSMN1; SMN2MAOB
SCHEMBL7182439 0.88 PDK2 (0.38) TDP1PLA2G1BATG4BMAOBMAOA
SCHEMBL7182795 0.86 MRGPRX4 (0.34) SMN1; SMN2AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL7180390 0.86 MAOB (0.40) SMN1; SMN2AKR1C4AKR1C3AKR1C2AKR1C1
Lithium SCHEMBL7188424 0.86 TDP1 (0.36) TDP1PLA2G1BATG4BSMN1; SMN2GAA
SCHEMBL7184590 0.84 SMN1; SMN2 (0.34) TDP1PLA2G1BATG4BSMN1; SMN2MAOB
Lithium SCHEMBL7186703 0.83 TDP1 (0.35) TDP1SMN1; SMN2LMNAMAPTMEN1
Lithium SCHEMBL7182577 0.82 CA12 (0.38) TDP1SMN1; SMN2AKR1C3AKR1C2GAA
SCHEMBL7182639 0.82 PDK2 (0.40) MAOBMAOAHPGD
SCHEMBL7180662 0.81 MAPK8 (0.33) MAOBMAOAGAAHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 TDP1 4234/4885PLA2G1B 2940/4885ATG4B 4705/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 TDP1 4275/4885PLA2G1B 2572/4885ATG4B 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.